India · Delayed Price · Currency is INR Nephro Care India Statistics
Total Valuation
NSE:NEPHROCARE has a market cap or net worth of INR 1.12 billion. The enterprise value is 954.90 million.
| Market Cap | 1.12B |
| Enterprise Value | 954.90M |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:NEPHROCARE has 16.49 million shares outstanding. The number of shares has increased by 8.07% in one year.
| Current Share Class | 16.49M |
| Shares Outstanding | 16.49M |
| Shares Change (YoY) | +8.07% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 61.44% |
| Owned by Institutions (%) | n/a |
| Float | 6.36M |
Valuation Ratios
The trailing PE ratio is 33.28.
| PE Ratio | 33.28 |
| Forward PE | n/a |
| PS Ratio | 1.26 |
| PB Ratio | 1.97 |
| P/TBV Ratio | 1.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 50.64 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 28.34 |
| EV / Sales | 1.08 |
| EV / EBITDA | 11.48 |
| EV / EBIT | 29.41 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.02
| Current Ratio | 2.02 |
| Quick Ratio | 1.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 20.72 |
Financial Efficiency
Return on equity (ROE) is 6.10% and return on invested capital (ROIC) is 5.77%.
| Return on Equity (ROE) | 6.10% |
| Return on Assets (ROA) | 2.88% |
| Return on Invested Capital (ROIC) | 5.77% |
| Return on Capital Employed (ROCE) | 5.65% |
| Weighted Average Cost of Capital (WACC) | 12.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 334 |
| Asset Turnover | 1.26 |
| Inventory Turnover | 23.45 |
Taxes
In the past 12 months, NSE:NEPHROCARE has paid 12.69 million in taxes.
| Income Tax | 12.69M |
| Effective Tax Rate | 27.36% |
Stock Price Statistics
The stock price has decreased by -35.98% in the last 52 weeks. The beta is 1.53, so NSE:NEPHROCARE's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | -35.98% |
| 50-Day Moving Average | 74.24 |
| 200-Day Moving Average | 100.16 |
| Relative Strength Index (RSI) | 43.96 |
| Average Volume (20 Days) | 13,500 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:NEPHROCARE had revenue of INR 887.35 million and earned 33.69 million in profits. Earnings per share was 2.04.
| Revenue | 887.35M |
| Gross Profit | 475.25M |
| Operating Income | 32.47M |
| Pretax Income | 46.38M |
| Net Income | 33.69M |
| EBITDA | 83.21M |
| EBIT | 32.47M |
| Earnings Per Share (EPS) | 2.04 |
Balance Sheet
The company has 165.02 million in cash and n/a in debt, with a net cash position of 165.02 million or 10.01 per share.
| Cash & Cash Equivalents | 165.02M |
| Total Debt | n/a |
| Net Cash | 165.02M |
| Net Cash Per Share | 10.01 |
| Equity (Book Value) | 569.03M |
| Book Value Per Share | 34.53 |
| Working Capital | 155.11M |
Cash Flow
In the last 12 months, operating cash flow was 22.11 million and capital expenditures -78.06 million, giving a free cash flow of -55.96 million.
| Operating Cash Flow | 22.11M |
| Capital Expenditures | -78.06M |
| Depreciation & Amortization | 50.74M |
| Net Borrowing | n/a |
| Free Cash Flow | -55.96M |
| FCF Per Share | -3.39 |
Margins
Gross margin is 53.56%, with operating and profit margins of 3.66% and 3.80%.
| Gross Margin | 53.56% |
| Operating Margin | 3.66% |
| Pretax Margin | 5.23% |
| Profit Margin | 3.80% |
| EBITDA Margin | 9.38% |
| EBIT Margin | 3.66% |
| FCF Margin | n/a |
Dividends & Yields
NSE:NEPHROCARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.07% |
| Shareholder Yield | -8.07% |
| Earnings Yield | 3.01% |
| FCF Yield | -5.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NSE:NEPHROCARE has an Altman Z-Score of 10.27 and a Piotroski F-Score of 5.
| Altman Z-Score | 10.27 |
| Piotroski F-Score | 5 |